Showing 3091-3100 of 5646 results for "".
- Mireca Signs Deal with Graybug Vision to Develop Treatments for Inherited Retinal Diseaseshttps://modernod.com/news/mireca-signs-deal-with-graybug-vision-to-develop-treatments-for-inherited-retinal-diseases/2480755/
- Researchers Identify How Multiple Genes Impact Vision Development and Result in Rare Sight Disorderhttps://modernod.com/news/researchers-identify-how-multiple-genes-impact-vision-development-and-result-in-rare-sight-disorder/2480744/
- Heru Featured in Scientific Program with Hands-On Demonstrations at the 2022 Vision Expo East Annual Meetinghttps://modernod.com/news/heru-featured-in-scientific-program-with-hands-on-demonstrations-at-the-2022-vision-expo-east-annual-meeting/2480739/Heru, a provider of vision diagnostics, announced that the company will be featuring two new testing moda
- Penn Researchers Develop Gene Therapy that Restores Dim-Light Vision in Dogshttps://modernod.com/news/penn-researchers-develop-gene-therapy-that-restores-dim-light-vision-in-dogs/2480723/In the journal Proceedings of the National Academy of Sciences, University of Pennsylvania researchers reported a major advance: a gene therapy that returns night vision to dogs born with congenital stationary night blindness
- Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI Surgical System in Pseudophakic Eyes with Open-Angle Glaucomahttps://modernod.com/news/sight-sciences-announces-first-patient-treated-in-trident-european-trial-to-evaluate-the-omni-surgical-system-in-pseudophakic-eyes-with-open-angle-glaucoma/2480722/Sight Sciences announced that the first patient has been treated in the novel TRIDENT clinical trial, designed to demonstrate the OMNI Surgical System with higher volume as a safe and effective standalone treatment option, compared to implantation of iStent inject (Glaukos), in
- LumiThera Announces US LIGHTSITE III Clinical Trial Meets Primary Efficacy Endpoint in Improving Vision in Dry AMD Patientshttps://modernod.com/news/lumithera-announces-us-lightsite-iii-clinical-trial-meets-primary-efficacy-endpoint-in-improving-vision-in-dry-amd-patients/2480712/LumiThera announced positive findings in its LIGHTSITE III multicenter clinical trial in non-neovascular (dry) age-related macular degeneration (AMD) subjects treated with the Valeda Light Delivery System. LIGHTSITE III, a prospective, double-masked, randomized, multicenter clinica
- Study Shows Eyenovia's Optejet Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutionshttps://modernod.com/news/study-shows-eyenovias-optejet-delivery-technology-reduces-conjunctival-cell-toxicity-from-preserved-ophthalmic-solutions/2480698/Eyenovia announced positive results from a research study conducted in collaboration with Pedram Hamrah, MD, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the ocular surface damage from latanoprost+benzalkonium chloride (BAK) treatment administered via
- Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink Therapyhttps://modernod.com/news/glaukos-announces-commencement-of-phase-2-corneal-health-clinical-program-for-third-generation-ilink-therapy/2480696/Glaukos announced that it has commenced a phase 2 clinical program for its third-generation iLink therapy designed to treat keratoconus. Glaukos’ iLink pharmaceutical platform consists of novel single-use drug formulations that are bio-activa
- Alcon Debuts Dailies Total1 for Astigmatism, Other Eye Care Innovations at SECO 2022https://modernod.com/news/alcon-debuts-dailies-total1-for-astigmatism-other-eye-care-innovations-at-seco-2022/2480694/
- Kala Pharmaceuticals Announces Eysuvis Now Covered on UnitedHealthcare Commercial and Cigna Medicarehttps://modernod.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-on-unitedhealthcare-commercial-and-cigna-medicare/2480681/Kala Pharmaceuticals announced that UnitedHealthcare, one of the largest commercial health care plans in the United States covering approximately 13 million people, has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies eff